Editas Medicine
Stock Forecast, Prediction & Price Target
Editas Medicine (EDIT) stock Price Target by analysts
$8
Potential upside: 205.34%
Editas Medicine price prediction
What is Editas Medicine stock analysts` prediction?
Editas Medicine stock forecast: Based on 3 Wall Street analysts` predicted price targets for Editas Medicine in the last 3 months, the avarage price target is $8, with a high forecast of $NaN. The average price target represents a 205.34% change from the last price of $2.62.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Editas Medicine stock Price Target by analysts
Full breakdown of analysts given Editas Medicine price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Gena Wang Barclays | 0% 0/1 | 10 months ago | $5 90.83% upside | $3.12 | StreetInsider | Previous targets (0) |
Yanan Zhu Wells Fargo | 0% 0/1 | 11 months ago | $9 243.51% upside | $3.29 | StreetInsider | Previous targets (0) |
Joel Beatty Robert W. Baird | 0% 0/2 | 11 months ago | $10 281.67% upside | $3.29 | StreetInsider | Previous targets (1) |
Greg Harrison Bank of America Securities | 0% 0/1 | about 1 year ago | $15 472.51% upside | $4.21 | StreetInsider | Previous targets (0) |
Joon Lee Truist Financial | 0% 0/3 | about 1 year ago | $12 358.01% upside | $4.24 | StreetInsider | Previous targets (2) |
Liisa Bayko Evercore ISI | 0% 0/1 | over 1 year ago | $7 167.17% upside | $5.1 | StreetInsider | Previous targets (0) |
Matthew Harrison Morgan Stanley | 50% 1/2 | over 1 year ago | $7 167.17% upside | $5.04 | StreetInsider | Previous targets (1) |
Dae Gon Ha Stifel Nicolaus | 0% 0/1 | almost 2 years ago | $17 548.85% upside | $6.92 | StreetInsider | Previous targets (0) |
Unknown Citigroup | N/A | almost 3 years ago | $11 319.84% upside | $9.96 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $8 205.34% upside | $10.64 | Benzinga | N/A |
Unknown Credit Suisse | N/A | almost 3 years ago | $13 396.18% upside | $11.01 | Benzinga | N/A |
Joon Lee Truist Financial | 0% 0/3 | almost 3 years ago | $35 1235.87% upside | $11.01 | TheFly | Previous targets (2) |
Unknown Chardan Capital | N/A | almost 3 years ago | $35 1235.87% upside | $11.01 | Benzinga | N/A |
Unknown RBC Capital | N/A | almost 3 years ago | $14 434.35% upside | $11.01 | Benzinga | N/A |
Unknown Oppenheimer | N/A | almost 3 years ago | $12 358.01% upside | $11.01 | Benzinga | N/A |
Matthew Harrison Morgan Stanley | 50% 1/2 | over 3 years ago | $24 816.03% upside | $24.41 | TipRanks Contributor | Previous targets (1) |
Joel Beatty Robert W. Baird | 0% 0/2 | almost 4 years ago | $44 1579.38% upside | $40.57 | TipRanks | Previous targets (1) |
Joon Lee Truist Financial | 0% 0/3 | almost 4 years ago | $80 2953.43% upside | $42.5 | TheFly | Previous targets (2) |
Editas Medicine Financial Estimates
Editas Medicine Revenue Estimates
Editas Medicine EBITDA Estimates
Editas Medicine Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $25.54M N/A | $19.71M -22.83% | $78.12M 296.32% | Avg: $24.82M Low: $16.99M High: $31.11M avg. -68.21% | Avg: $62.22M Low: $16.96M High: $107.09M avg. 150.59% | Avg: $187.78M Low: $51.20M High: $323.21M avg. 201.80% | Avg: $301.13M Low: $82.10M High: $518.31M avg. 60.36% |
Net Income
% change YoY
| $-185.10M N/A | $-204.35M -10.39% | $-153.21M 25.02% | Avg: $-250.37M Low: $-262.84M High: $-130.66M avg. -63.40% | Avg: $-261.40M Low: $-233.97M High: $-129.14M avg. -4.40% | Avg: $-124.49M Low: $-241.22M High: $-6.78M avg. 52.37% | Avg: $-58.20M Low: $-112.78M High: $-3.17M avg. 53.24% |
EBITDA
% change YoY
| $-193.14M N/A | $-225.95M -16.98% | $-163.11M 27.80% | Avg: $-24.82M Low: $-31.11M High: $-16.99M avg. 84.77% | Avg: $-62.22M Low: $-107.09M High: $-16.96M avg. -150.59% | Avg: $-187.78M Low: $-323.21M High: $-51.20M avg. -201.80% | Avg: $-301.13M Low: $-518.31M High: $-82.10M avg. -60.36% |
EPS
% change YoY
| -$2.74 N/A | -$2.98 -8.75% | -$2.02 32.21% | Avg: -$2.55 Low: -$3.46 High: -$1.72 avg. -26.21% | Avg: -$2.49 Low: -$3.08 High: -$1.7 avg. 2.38% | Avg: -$1.64 Low: -$3.18 High: -$0.09 avg. 34.15% | Avg: -$0.77 Low: -$1.48 High: -$0.04 avg. 53.24% |
Operating Expenses
% change YoY
| $218.69M N/A | $245.66M 12.33% | $247.30M 0.66% | Avg: $56.36M Low: $38.58M High: $70.63M avg. -77.20% | Avg: $141.23M Low: $38.51M High: $243.10M avg. 150.59% | Avg: $426.26M Low: $116.22M High: $733.69M avg. 201.80% | Avg: $683.56M Low: $186.38M High: $1.17B avg. 60.36% |
FAQ
What is Editas Medicine stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 9.45% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -262.84M, average is -250.37M and high is -130.66M.
What is Editas Medicine stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 86.13% in 2025-2028.
We have gathered data from 12 analysts. Their low revenue estimate is $16.99M, average is $24.82M and high is $31.11M.
What is Editas Medicine stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.89% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$3.46, average is -$2.55 and high is $-1.72.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Editas Medicine stock. The most successful analyst is Gena Wang.